2bPrecise and The Innovation Institute to Deliver Robust Pharmacogenomics Platform, GeneFolio, to the Point of Care

2bPrecise and The Innovation Institute to Deliver Robust Pharmacogenomics Platform, GeneFolio, to the Point of Care

2bPrecise®, LLC, and The Innovation Institute announced today that they have entered into an agreement that lays the foundation for 2bPrecise to deliver a pharmacogenomics knowledge base to the point of care for The Innovation Institute’s network of member providers, as well as others beyond the network.

The Innovation Institute, a for-profit limited liability company established in 2013 and based in La Palma, Calif., is comprised of six “member owner” health systems – one of which, Avera Health, developed GeneFolio®, a robust drug-drug-gene test and knowledge base, which incorporates pharmacist-based expertise into every test result. The agreement with 2bPrecise, which offers an industry-leading precision medicine platform, is intended to enable GeneFolio to be accessed within the provider workflow across all Innovation Institute health systems, as well as others.

GeneFolio was launched within the Avera footprint in the summer of 2017. “Pharmacogenomics is poised for rapid health care adoption to improve treatment success and Avera has been developing and advancing the integration for almost a decade,” said Krista Bohlen, PharmD, Director of Personalized Medicine at the Avera Institute for Human Genetics. “We’re excited to offer this test, developed by Avera scientists, laboratory personnel and pharmacists that will serve as a guide for a patient’s care for decades to come.”

GeneFolio draws upon results from a simple saliva or blood sample. GeneFolio tests multiple genes that impact medications in three main classes: pain, depression and other psychiatric disorders, and statins for cholesterol and certain types of blood thinners, with others in development.

Priced affordably, GeneFolio results are delivered in a color-coded report that shows which medications will be metabolized well by the patient, and which should be used with caution or not used at all. The GeneFolio test can be taken once and then results can be consulted for years to come as other medications are prescribed.

While GeneFolio doesn’t tell providers what to prescribe, it gives them an additional tool to hone in and prescribe the most effective medications, which can mean fewer side effects, faster recovery and lower costs.

The 2bPrecise platform enables the results achieved through GeneFolio to be harmonized and delivered to clinicians in an actionable format – not only within the Avera Health system, located across a multi-state region in the Midwest, but across The Innovation Institute’s network, which includes five other prominent health systems representing 125 hospitals in 20 states.

“The GeneFolio knowledge base is truly revolutionary,” said Larry Stofko, Executive Vice President of The Innovation Institute, “and 2bPrecise is the perfect partner to help us achieve our mission.” He concluded, “Together, we can enable physicians to take these insights, and order the medications or therapies most likely to be effective with each individual patient. This means improved patient outcomes and a decrease in the overall cost of care.”

The 2bPrecise platform is cloud-based, scalable and EHR-agnostic. Clinicians can access genomic insights such as those provided by GeneFolio without leaving their preferred workflows, and leverage the information to make optimal testing, diagnostic and therapeutic decisions.

“We are delighted to work with The Innovation Institute to offer the most advanced genomic and pharmacogenomics guidance tools, providing exceptional genomic and clinical care for patients,” said Assaf Halevy, CEO of 2bPrecise, a wholly owned subsidiary of Allscripts Healthcare Solutions. “We share its mission and dedication to improve the health and wellbeing of all individuals dealing with life-altering diseases.”